查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012300

HIV疫苗市场：按疫苗类型、给药途径、标靶抗原和最终用户分類的全球市场预测 – 2026–2032年

HIV Vaccines Market by Vaccine Type, Route Of Administration, Target Antigen, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年 HIV 疫苗市场价值为 4.3852 亿美元，预计到 2025 年将成长至 4.9438 亿美元，复合年增长率为 13.27%，到 2032 年将达到 11.8844 亿美元。

主要市场统计数据
基准年 2024 4.3852亿美元
预计年份：2025年 4.9438亿美元
预测年份 2032 1,188,440,000 美元
复合年增长率 (%) 13.27%

简要概述正在重塑 HIV 疫苗研发和计画重点的协同科学、监管和营运趋势。

爱滋病疫苗的研发在免疫学、病毒学和全球公共卫生策略的交叉领域中发挥着至关重要的作用。抗原设计、递送平台和免疫调节技术的最新科学进展重新定义了技术上可实现的范围，而监管环境和临床试验设计也在不断调整以适应新的方法。相关人员公共卫生机构、学术联盟和私人研发机构在内的各利益相关方，都在努力应对由复杂的科学权衡、不断变化的社会期望以及对永续生产和分销方式的需求所构成的挑战。

平台多样化、给药途径优化、监管协调和合作模式如何共同改变爱滋病疫苗策略。

在爱滋病疫苗领域，正在发生多项变革性变化，这些变化正在重新定义研究策略、投资重点和合作框架。首先，平台多样化正在推动并行研发路径的形成。虽然重组蛋白和类病毒颗粒（VLPs）等传统方法在某些免疫谱中仍发挥重要作用，但基于核苷酸的平台，例如常规mRNA和自扩增mRNA，由于其设计週期短、抗原呈现能力灵活，正吸引越来越多的关注。同时，病毒载体和胜肽策略也在不断改进，以提高安全性、增强免疫反应的持久性以及靶向细胞介导免疫。

本研究评估了 2025 年关税变化将如何重塑整个 HIV 疫苗价值链的采购、製造地和合作生产策略。

预计在2025年前后，关税政策的变化将对疫苗供应链、筹资策略和跨境合作带来新的挑战。某些原材料、组件和成品关税的提高可能会影响製造地的成本竞争力，并影响成品疫苗和关键中间体的生产地点选择。这些变化使得供应链透明度和策略采购（减少对单一国家供应商关键试剂和耗材的依赖）变得更加重要。

将疫苗类型、平台技术、给药途径、终端用户趋势和分销方式与策略决策联繫起来的综合细分洞察。

详细的細項分析揭示了产品策略、技术选择、给药途径、用户需求和通路如何相互作用，从而决定研发和商业化的优先顺序。在评估疫苗类型时，预防性疫苗包括传统的灭活病毒疫苗、减毒活病毒疫苗、重组蛋白製剂和类病毒颗粒（VLP）候选疫苗，每种疫苗都有不同的免疫抗原性特征和生产挑战。另一方面，治疗性候选疫苗针对不同的终点和患者群体，这会影响临床试验设计以及与医疗保健系统的长期合作。技术选择涵盖DNA、mRNA、胜肽和病毒载体平台，其中mRNA本身可进一步区分为传统的mRNA构建体和旨在提高抗原表达和给药效率的自扩增mRNA。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略挑战将决定监管协调和实施准备。

区域趋势对爱滋病疫苗的研发、监管策略和部署策略规划至关重要。在美洲，各监管辖区拥有先进的临床试验基础设施和多元化的支付方环境，这有利于分阶段进行临床试验，并促进与学术机构和商业生产商的伙伴关係。由于各国的智慧财产权框架和采购机制各不相同，跨境策略通常优先考虑儘早与各国监管机构和支付方接洽，以建构符合报销预期的证据材料。

领先的研究机构、开发公司和製造合作伙伴如何建立其产品组合、合作关係和製造方法，以获得转化优势？

构成爱滋病疫苗生态系统的关键机构正在根据科学进步和不断变化的营运限制调整其产品组合和合作方式。公共研究机构持续提供基础免疫学见解以支持转化项目，而製药和生物技术开发公司则透过将新型抗原设计与先进的递送平台相结合，优化免疫反应的持久性和广度。战略合作伙伴关係通常将平台专家与提供临床试验基础设施和区域生产能力的机构相结合，从而实现更快的规模化生产和更有效率的受试者招募。

专案领导者需要采取切实可行的策略行动，以平衡平台选择、供应链韧性、监管参与和公平准入伙伴关係。

产业领导者应将短期战术性行动与策略蓝图相协调，以平衡科学风险、营运韧性和市场准入目标。在早期产品组合中，应优先考虑平台独立性，以确保在重组蛋白、类病毒颗粒、核苷酸构建体和病毒载体之间保持选择性。这种方法允许根据临床数据揭示的保护性相关性和持久性讯号调整项目。同时，应投资特定疗法的下游能力，例如製剂科学、低温运输物流和给药途径优化，以减少后期转化研究的阻力。

透过将对专家的直接访谈与二手科学和监管证据相结合，我们透过高度透明和可重复的调查方法，为可操作的方案提供见解。

本报告整合了一手和二手资料，建构了一个严谨且可重复的爱滋病疫苗研发现状图景。一手资料包括对临床研究人员、生产专家、监管顾问和采购相关人员的结构化访谈，以及来自积极应对研发和规模化挑战的后期专案经理的匿名定性回馈。二手资料则利用同侪审查文献、已发布的监管指南、临床试验註册数据和会议报告，对科学趋势进行多角度检验，并为转化医学假设提供支持。

综合考虑技术、监管、供应链和区域因素，制定将爱滋病毒疫苗创新转化为可用解决方案的切实可行的途径。

总之，当前爱滋病疫苗的发展现状呈现出技术多样化加速、监管预期不断变化以及对供应链和区域部署实际情况日益关注的特征。那些保持平台柔软性、投资于与其所选给药途径相匹配的运营能力并积极与当地相关人员合作的研发者，将更有利于把科学进步转化为适销产品。关税和贸易政策的变化凸显了製定具有韧性的采购和生产策略的重要性，而市场碎片化和区域趋势则强调了采取能够反映最终用户需求和分销管道实际情况的个人化方法的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：爱滋病疫苗市场：依疫苗类型划分

  • 为了预防
    • 胜肽疫苗
    • 减毒活病毒疫苗
    • DNA疫苗
    • 药效疫苗
  • 治疗

第九章：爱滋病疫苗市场：依给药途径划分

  • 肌肉内部
  • 鼻内
  • 皮下

第十章：爱滋病疫苗市场：以标靶抗原划分

  • 包膜糖蛋白（Env）
  • 内部 Gag 蛋白
  • Pol蛋白

第十一章：爱滋病疫苗市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构
  • 公共卫生机构与政府

第十二章 爱滋病疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：爱滋病疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 爱滋病疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：爱滋病疫苗市场

第十六章 中国：爱滋病疫苗市场

第十七章 竞争格局

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • AlphaVax, Inc.
  • BioNTech SE
  • GeoVax Labs, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ImmunityBio, Inc.
  • Johnson & Johnson Services, Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Vir Biotechnology, Inc
Product Code: MRR-4312A385A507

The HIV Vaccines Market was valued at USD 438.52 million in 2024 and is projected to grow to USD 494.38 million in 2025, with a CAGR of 13.27%, reaching USD 1,188.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 438.52 million
Estimated Year [2025] USD 494.38 million
Forecast Year [2032] USD 1,188.44 million
CAGR (%) 13.27%

Concise orientation to the converging scientific, regulatory, and operational forces reshaping HIV vaccine development and program priorities

HIV vaccine development occupies a pivotal role at the intersection of immunology, virology, and global public health strategy. Recent scientific advances in antigen design, delivery platforms, and immune modulation techniques have reframed what is technically achievable, while regulatory frameworks and clinical trial designs continue to adapt to novel modalities. Stakeholders across public health institutions, academic consortia, and private developers are navigating a landscape shaped by complex scientific trade-offs, evolving public expectations, and the need for sustainable manufacturing and distribution approaches.

This executive summary aims to synthesize the most consequential developments and to surface strategic implications for decision-makers. It clarifies how shifts in platform technology preferences, regulatory alignment, and geopolitical dynamics are influencing priorities across development portfolios. The summary also highlights how route of administration choices, end-user requirements, and distribution channels intersect with technology selection and clinical strategy. By framing these factors together, the introduction sets the stage for actionable insight that supports program prioritization, partnership formation, and operational planning across research, clinical, and commercial stakeholders.

How platform diversification, administration route optimization, regulatory harmonization, and collaborative models are jointly transforming HIV vaccine strategies

The HIV vaccine landscape is undergoing several transformative shifts that are redefining research strategies, investment priorities, and the architecture of collaboration. First, platform diversification is driving parallel development pathways: while traditional approaches like recombinant protein and virus-like particle constructs retain importance for certain immune profiles, nucleotide-based platforms such as conventional mRNA and self-amplifying mRNA are catalyzing renewed interest due to their rapid design cycles and flexible antigen presentation. At the same time, viral vectors and peptide strategies continue to be refined to improve safety, durability of response, and targeted cellular immunity.

Second, integration of immunogen design with delivery route selection is emerging as a critical determinant of clinical strategy. Intramuscular administration remains the default for many candidates, but intranasal and subcutaneous routes are being reexamined for mucosal immunity and dose-sparing advantages respectively. Third, regulatory agencies are increasingly emphasizing harmonized endpoints, adaptive trial designs, and real-world data integration, which accelerates translational pathways but requires robust post-authorization evidence plans. Finally, collaboration models are shifting: multi-stakeholder consortia, public-private partnerships, and novel licensing arrangements are becoming standard mechanisms to balance scientific risk, capital intensity, and global access objectives. These shifts collectively expand the set of feasible strategies for program leaders while raising the premium on integrated technical, regulatory, and commercial planning.

Assessing how 2025 tariff shifts are reshaping sourcing, manufacturing footprints, and collaborative production strategies across the HIV vaccine value chain

Tariff policy changes announced in and around 2025 have introduced a new set of considerations for vaccine supply chains, procurement strategies, and cross-border collaboration. Increased duties on certain raw materials, components, and finished products can impact the cost competitiveness of manufacturing footprints and influence decisions about where to site production for finished vaccines or key intermediates. These dynamics amplify the importance of supply chain visibility and of strategic sourcing that reduces dependence on single-country suppliers for critical reagents and consumables.

Beyond direct cost effects, tariff shifts can create operational frictions that extend lead times and complicate inventory planning. Manufacturers and distributors respond by diversifying supplier networks, increasing onshore or nearshore manufacturing capacity, and renegotiating long-term supply agreements to incorporate tariff contingencies. Procurement teams must also adjust contracting language to address customs compliance, tariff mitigation clauses, and potential regulatory variances that arise when products cross multiple jurisdictions.

Importantly, tariffs can influence collaborative structures: research collaborations and manufacturing partnerships may emphasize in-region production and technology transfer to avoid cross-border cost penalties and to align with national industrial policies. Policymakers and industry alike are assessing how tariff instruments affect equitable access objectives, with a growing emphasis on cooperative mechanisms that preserve affordability while supporting resilient manufacturing ecosystems.

Integrated segmentation insights that connect vaccine type, platform technology, administration route, end-user dynamics, and distribution choices to strategic decision-making

A nuanced view of segmentation reveals how product strategy, technology choice, administration route, user needs, and distribution pathways interact to determine development and commercialization priorities. When evaluating vaccine type, preventive approaches encompass traditional inactivated virus, live attenuated constructs, recombinant protein assets, and virus-like particle candidates, each offering distinct immunogenicity profiles and manufacturing implications; therapeutic candidates pursue different endpoints and patient cohorts, influencing clinical design and long-term engagement with healthcare systems. Technology selection spans DNA, mRNA, peptide, and viral vector platforms, where the mRNA category itself differentiates between conventional mRNA constructs and self-amplifying mRNA that aim to enhance antigen expression and dose efficiency.

Route of administration considerations-intramuscular, intranasal, and subcutaneous-affect both the immunological rationale and the operational logistics of deployment, shaping cold chain requirements and administration training. End-user segmentation highlights divergent requirements from clinics, hospitals, pharmaceutical companies, and research institutes; within clinics, the distinction between hospital-affiliated clinics and standalone clinics informs procurement channels and patient flow design, while private and public hospitals exhibit different purchasing frameworks and budgetary cycles. Distribution channel choices, including direct sales, online sales, and retail pharmacies, further determine engagement models with healthcare providers and patient access pathways. Together, these segmentation dimensions create a multidimensional decision matrix for developers and program managers that must be reconciled across scientific, regulatory, and commercial timelines.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory alignment and deployment readiness

Regional dynamics are central to strategic planning for HIV vaccine development, regulatory strategy, and deployment. In the Americas, regulatory jurisdictions exhibit a mix of advanced clinical trial infrastructure and diverse payer landscapes, which encourages staged clinical pathways and partnerships with both academic centers and commercial manufacturers. Intellectual property frameworks and procurement mechanisms vary across countries, so cross-border strategies often prioritize early engagement with national regulators and payers to align evidence packages with reimbursement expectations.

Europe, Middle East & Africa presents a complex mosaic where regulatory harmonization initiatives coexist with significant variability in manufacturing capacity and healthcare access. This region emphasizes the need for flexible development plans that accommodate diverse clinical trial populations and that integrate technology transfer elements to build sustainable local capacity. Engagement with regional public health bodies and multilateral procurement entities is often essential to ensure broad access and to coordinate rollout priorities.

Asia-Pacific demonstrates a range of capabilities from high-volume manufacturing hubs to rapidly modernizing regulatory systems and extensive clinical trial networks. Developers frequently pursue regional manufacturing arrangements and strategic licensing to leverage production scale and to navigate national regulatory requirements. Across all regions, local stakeholder relationships, regulatory clarity, and manufacturing resilience remain key determinants of how quickly and effectively vaccine candidates progress from development to delivery.

How leading research institutes, developers, and manufacturing partners are structuring portfolios, collaborations, and manufacturing approaches to gain translational advantage

Leading organizations across the HIV vaccine ecosystem are evolving their portfolios and partnership approaches in response to scientific progress and shifting operational constraints. Public research institutions continue to supply fundamental immunology insights that feed translational programs, while pharmaceutical and biotech developers are combining novel antigen designs with advanced delivery platforms to optimize immune durability and breadth. Strategic collaborations frequently pair platform specialists with organizations that provide clinical trial infrastructure or regional manufacturing capacity, enabling faster scale-up and more efficient study enrollment.

Companies that integrate modular manufacturing capabilities and flexible CMC (chemistry, manufacturing, and controls) processes tend to manage clinical transitions more smoothly. Firms investing in cold chain innovation, quality-by-design manufacturing, and scalable analytics strengthen their ability to support multi-regional rollouts. Meanwhile, contract development and manufacturing organizations (CDMOs) that offer end-to-end services and regulatory experience are increasingly central to program timelines, especially where in-region production or technology transfer is required. Across the ecosystem, competitive advantage accrues to entities that align scientific novelty with operational execution, regulatory foresight, and collaborative agility.

Practical strategic actions for program leaders to balance platform optionality, supply chain resilience, regulatory engagement, and equitable access partnerships

Industry leaders should align near-term tactical actions with a strategic roadmap that balances scientific risk, operational resilience, and access objectives. Prioritize platform agnosticism in early-stage portfolios to preserve optionality between recombinant protein, virus-like particles, nucleotide-based constructs, and viral vectors; this approach allows programs to pivot as clinical data clarifies correlates of protection and durability signals. Simultaneously, invest in modality-specific downstream capabilities such as formulation science, cold chain logistics, and route-of-administration optimization to reduce late-stage translational friction.

Strengthen supply chain resilience by diversifying suppliers for critical inputs, exploring nearshoring or regional manufacturing partnerships, and embedding tariff contingency clauses in procurement contracts. Enhance regulatory strategy by engaging regulators early and pursuing harmonized endpoints and adaptive trial frameworks that support accelerated evidence generation while maintaining robust safety oversight. Finally, develop partnership models that enable technology transfer, local capacity building, and equitable access arrangements; such models should include clear governance, IP management strategies, and shared go-to-market plans that align incentives across public and private stakeholders. These actions collectively reduce program risk and increase the likelihood that promising candidates can progress efficiently from clinical proof-of-concept to broad availability.

Transparent, reproducible research methodology combining primary expert interviews and secondary scientific and regulatory evidence to inform actionable program insights

This report synthesizes primary and secondary inputs to construct a rigorous, reproducible view of the HIV vaccine landscape. Primary inputs include structured interviews with clinical investigators, manufacturing experts, regulatory advisors, and procurement stakeholders, combined with anonymized qualitative feedback from late-stage program managers who are actively navigating development and scale-up challenges. Secondary inputs draw on peer-reviewed literature, public regulatory guidance, clinical trial registries, and conference disclosures to triangulate scientific trends and to validate translational assumptions.

Analysis prioritizes methodological transparency: assumptions about technology performance, supply chain constraints, and regulatory pathways are documented, and sensitivity checks explore alternative scenarios for platform adoption and manufacturing strategies. Where applicable, conclusions emphasize evidence-based linkages rather than speculative projections. The methodology supports custom filtering by technology, route of administration, and region, enabling tailored extractable insights for decision-makers who require focused analysis for partnerships, procurement, or clinical strategy development.

Synthesis of technology, regulatory, supply chain, and regional considerations that define the practical pathways to translating HIV vaccine innovation into accessible solutions

In conclusion, the HIV vaccine landscape is characterized by accelerating technological diversity, evolving regulatory expectations, and heightened attention to supply chain and regional deployment realities. Developers who maintain platform flexibility, invest in operational capabilities that align with chosen administration routes, and proactively engage with regional stakeholders will be better positioned to translate scientific advances into deliverable products. Tariff and trade policy shifts underscore the importance of resilient sourcing and manufacturing strategies, while segmentation and regional dynamics highlight the need for tailored approaches that reflect end-user requirements and distribution channel realities.

The path from promising immunogen to widely accessible vaccine requires integrated planning across science, manufacturing, regulation, and commercial pathways. Strategic partnerships, modular manufacturing approaches, and early regulatory dialogue will continue to accelerate program progression. Ultimately, successful programs will be those that pair technical innovation with pragmatic execution plans that anticipate policy and logistical constraints while centering equitable access objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Vaccines Market, by Vaccine Type

  • 8.1. Preventive
    • 8.1.1. Peptide Vaccines
    • 8.1.2. Live-attenuated Vaccines
    • 8.1.3. DNA Vaccines
    • 8.1.4. mRNA Vaccines
  • 8.2. Therapeutic

9. HIV Vaccines Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intranasal
  • 9.3. Subcutaneous

10. HIV Vaccines Market, by Target Antigen

  • 10.1. Envelope Glycoproteins (Env)
  • 10.2. Internal Gag Protein
  • 10.3. Pol Proteins

11. HIV Vaccines Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Public Health Agencies & Governments

12. HIV Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. HIV Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. HIV Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States HIV Vaccines Market

16. China HIV Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. AlphaVax, Inc.
  • 17.6. BioNTech SE
  • 17.7. GeoVax Labs, Inc.
  • 17.8. Gilead Sciences, Inc.
  • 17.9. GlaxoSmithKline PLC
  • 17.10. ImmunityBio, Inc.
  • 17.11. Johnson & Johnson Services, Inc.
  • 17.12. Moderna, Inc.
  • 17.13. Pfizer Inc.
  • 17.14. Vir Biotechnology, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY ENVELOPE GLYCOPROTEINS (ENV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY INTERNAL GAG PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV VACCINES MARKET SIZE, BY POL PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTH AGENCIES & GOVERNMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA HIV VACCINES MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA HIV VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)